Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials.
Brandon M NathanDavid BoulwareSusan GeyerMark A AtkinsonPeter ColmanRobin GolandWilliam RussellJohn M WentworthDarrell M WilsonCarmella Evans-MolinaDiane WherrettJay S SkylerAntoinette MoranJay M Sosenkonull nullPublished in: Diabetes care (2017)
The findings suggest that incident dysglycemia without Index60 ≥1.00 is a suboptimal prediagnostic end point for type 1 diabetes. Measures that include both glucose and C-peptide levels, such as Index60 ≥1.00, appear better suited as prediagnostic end points.